EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma

Ghassan K Abou-Alfa iD, Xiaoliang Wang iD, Christina M Parrinello, Anala Gossai, Richard Kim iD, Kelly Magee, Rebecca A Miksad iD

Cancer · 2023

DOI: 10.1002/cncr.34754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Ghassan K Abou-Alfa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Flatiron Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials suggest α‐fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real‐world settings is unclear.

Methods

Patients with advanced hepatocellular carcinoma between January 1, 2011, and June 30, 2021, first‐line tyrosine kinase inhibitor, and baseline and posttreatment AFP values (closest to 8 ± 2 weeks after first‐line initiation) were included. AFP reduction was defined as ≥20% decrease from baseline vs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis CHumansalpha-FetoproteinsPrognosisRetrospective Studies

Stichwörter der Autor:innen

alpha-fetoproteinhepatocellular carcinomaprognostic factorprogression-free survivalsurvival

Substanzen

alpha-Fetoproteins

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Weill Medical College at Cornell University, New York, New York, USA.
  • Flatiron Health, Inc., New York, New York, USA.
  • Pine Mountain Consulting, LLC, Redding, Colorado, USA.
  • Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Hematology and Oncology, Boston Medical Center, Boston, Massachusetts, USA.

ORCID-Profile: Ghassan K Abou-Alfa, Xiaoliang Wang, Richard Kim, Rebecca A Miksad

Förderung

  • Flatiron Health

Zitieren

APA

Abou-Alfa, G. K., Wang, X., Parrinello, C. M., Gossai, A., Kim, R., Magee, K., & Miksad, R. A. (2023). Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma. Cancer. https://doi.org/10.1002/cncr.34754

Vancouver

Abou-Alfa GK, Wang X, Parrinello CM, Gossai A, Kim R, Magee K, et al. Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma. Cancer. 2023. doi:10.1002/cncr.34754

BibTeX
@article{AbouAlfa2023,
  author = {Abou-Alfa, Ghassan K and Wang, Xiaoliang and Parrinello, Christina M and Gossai, Anala and Kim, Richard and Magee, Kelly and Miksad, Rebecca A},
  title = {Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34754}
}
Kostenlos starten →